BACKGROUND AND PURPOSE: Cyclophosphamide induces urotoxicity characterized by the development of cystitis, which involves bladder overactivity and inflammation. Here, we investigated the roles of chemokine receptor 2 (CXCR2) and transient receptor potential vanilloid 1 (TRPV1) channels in a rat model of cyclophosphamide-induced cystitis. EXPERIMENTAL APPROACH: Cystitis induced by cyclophosphamide in rats was assessed by gross morphology, histology and immunohistochemistry of bladder tissue. mRNA for CXCR2 and TRPV1 channels were measured by RT-PCR. Nociceptive responses in paw and abdomen, along with cystometric measures were recorded. KEY RESULTS: Cyclophosphamide, i.p., induced pain behaviour, bladder inflammation and voiding dysfunction. The CXCR2 antagonist, SB225002, the TRPV1 channel antagonist, SB366791 or their combination reduced the mechanical hypersensitivity of paw and abdominal area and nociceptive behaviour after cyclophosphamide. Cyclophosphamide-induced cystitis was characterized by haemorrhage, oedema, neutrophil infiltration and other inflammatory changes, which were markedly decreased by the antagonists. Up-regulation of CXCR2 and TRPV1 mRNA in the bladder after cyclophosphamide was inhibited by SB225002, SB366791 or their combination. Expression of CXCR2 and TRPV1 channels was increased in the urothelium after cyclophosphamide. Bladder dysfunction was shown by increased number of non-voiding contractions (NVCs) and bladder pressures and a reduction in bladder capacity (BC), voided volume (VV) and voiding efficiency (VE). SB225002 or its combination with SB366791 reduced bladder pressures, whereas SB225002, SB366791 or their combination increased BC, VV and VE, and also reduced the number of NVCs. CONCLUSIONS AND IMPLICATIONS: CXCR2 and TRPV1 channels play important roles in cyclophosphamide-induced cystitis in rats and could provide potential therapeutic targets for cystitis.
BACKGROUND AND PURPOSE:Cyclophosphamide induces urotoxicity characterized by the development of cystitis, which involves bladder overactivity and inflammation. Here, we investigated the roles of chemokine receptor 2 (CXCR2) and transient receptor potential vanilloid 1 (TRPV1) channels in a rat model of cyclophosphamide-induced cystitis. EXPERIMENTAL APPROACH: Cystitis induced by cyclophosphamide in rats was assessed by gross morphology, histology and immunohistochemistry of bladder tissue. mRNA for CXCR2 and TRPV1 channels were measured by RT-PCR. Nociceptive responses in paw and abdomen, along with cystometric measures were recorded. KEY RESULTS:Cyclophosphamide, i.p., induced pain behaviour, bladder inflammation and voiding dysfunction. The CXCR2 antagonist, SB225002, the TRPV1 channel antagonist, SB366791 or their combination reduced the mechanical hypersensitivity of paw and abdominal area and nociceptive behaviour after cyclophosphamide. Cyclophosphamide-induced cystitis was characterized by haemorrhage, oedema, neutrophil infiltration and other inflammatory changes, which were markedly decreased by the antagonists. Up-regulation of CXCR2 and TRPV1 mRNA in the bladder after cyclophosphamide was inhibited by SB225002, SB366791 or their combination. Expression of CXCR2 and TRPV1 channels was increased in the urothelium after cyclophosphamide. Bladder dysfunction was shown by increased number of non-voiding contractions (NVCs) and bladder pressures and a reduction in bladder capacity (BC), voided volume (VV) and voiding efficiency (VE). SB225002 or its combination with SB366791 reduced bladder pressures, whereas SB225002, SB366791 or their combination increased BC, VV and VE, and also reduced the number of NVCs. CONCLUSIONS AND IMPLICATIONS: CXCR2 and TRPV1 channels play important roles in cyclophosphamide-induced cystitis in rats and could provide potential therapeutic targets for cystitis.
Authors: Barbara Frias; Ana Charrua; Antonio Avelino; Martin C Michel; Francisco Cruz; Celia D Cruz Journal: BJU Int Date: 2012-04-30 Impact factor: 5.588
Authors: André A Santos; Paulo C Leal; Maria I A Edelweiss; Tiago Giuliani Lopes; João B Calixto; Fernanda B Morrone; Maria M Campos Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2010-09-01 Impact factor: 3.000
Authors: Denise M Marotta; Robson Costa; Emerson M Motta; Elizabeth S Fernandes; Rodrigo Medeiros; Nara L M Quintão; Maria M Campos; João B Calixto Journal: Biochem Pharmacol Date: 2009-04-01 Impact factor: 5.858
Authors: M M Barsante; T M Cunha; M Allegretti; F Cattani; F Policani; C Bizzarri; W L Tafuri; S Poole; F Q Cunha; R Bertini; M M Teixeira Journal: Br J Pharmacol Date: 2007-09-24 Impact factor: 8.739
Authors: R B M Silva; N D M Sperotto; E L Andrade; T C B Pereira; C E Leite; A H de Souza; M R Bogo; F B Morrone; M V Gomez; M M Campos Journal: Br J Pharmacol Date: 2014-12-15 Impact factor: 8.739
Authors: Zhiwei Feng; Larry V Pearce; Yu Zhang; Changrui Xing; Brienna K A Herold; Shifan Ma; Ziheng Hu; Noe A Turcios; Peng Yang; Qin Tong; Anna K McCall; Peter M Blumberg; Xiang-Qun Xie Journal: AAPS J Date: 2016-03-21 Impact factor: 4.009